High Survival Rates With Ryoncil in EIND Program

Emphasize Importance of Earlier Use in Both Pediatric and Adult Patients

Published on Feb. 11, 2026

Got story updates? Submit your updates here. ›

Mesoblast Limited, a global leader in allogeneic cellular medicines, has reported high survival rates with its product Ryoncil in the Expanded Access Program (EIND) for both pediatric and adult patients. The findings highlight the importance of using Ryoncil earlier in the treatment process.

Why it matters

The high survival rates seen with Ryoncil in the EIND program suggest that this cellular therapy could be an effective treatment option for patients, particularly if used earlier in the disease process. This is significant as it could lead to improved outcomes for those suffering from the conditions Ryoncil is approved to treat.

The details

Mesoblast's Ryoncil is an allogeneic cellular medicine that has been approved for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) in children and adults. The company reported that in the EIND program, which provides access to investigational treatments, Ryoncil demonstrated high survival rates in both pediatric and adult patients.

  • The findings were reported on February 11, 2026.

The players

Mesoblast Limited

A global leader in allogeneic cellular medicines and the developer of Ryoncil.

Got photos? Submit your photos here. ›

The takeaway

The high survival rates seen with Ryoncil in the EIND program suggest that this cellular therapy could be an effective treatment option, particularly if used earlier in the disease process. This could lead to improved outcomes for patients suffering from the conditions Ryoncil is approved to treat.